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2011 Presidential Address:
From Classroom to Courtroom to Clinic—
Closing the Gaps in Human Genetics Education1
Lynn B. Jorde2,*In this address, Iwill talk about some current gaps inhuman
genetics education. I will focus on two quite different areas
in which we need to improve the knowledge of our fellow
professionals and the general public: the use and interpreta-
tion of genetic testing and the understanding and appreci-
ation of the science of evolution. I will conclude with an
example in which these and other gaps are being closed
through an educational program for the judiciary.
Our field has seen tremendous progress during the past
two decades. The number of Mendelian conditions for
which a molecular basis has been identified has increased
from fewer than 200 in 1990 to more than 3,000 in
2011.1 This in turn has led to progress in the identification
of disease-causing mutations, genetic testing, and the diag-
nosis of genetic disease. The number of diseases for which
genetic testing is available has increased from about 100 in
1993 to nearly 2500 today (see Web Resources).1This article is based on the address given by the author at the meeting of the In
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The AmeThis explosion of information has produced an educa-
tion gap among health-care professionals. A recent survey
of 10,000 U.S. physicians showed that nearly all of them
agreed that genetic variation influences drug therapy.2 Yet
only 26% reported that they had education in the use of
genetic testing. Only 10% felt that they were able to put
pharmacogenetic testing to good use. This gap in under-
standing is accentuated by the rise of direct-to-consumer
testing, inwhich consumers can receive information about
ancestry, disease-associated variants, and possible risk of
disease for more than 400 health-related conditions.3
They can learn about potential sensitivity to drugs such as
Warfarin, Clopidogrel, and Abacavir. Information is also
available about approximate relative risks for developing
diseases such as age-related macular degeneration or type
2 diabetes. Increasingly, health-care professionals are being
asked to interpret these results for their patients.4
To better understand the results of genetic testing, we
might find it useful to make some comparisons. A loss-of-
function mutation in APC can confer a lifetime risk of
colon cancer of virtually 100%, compared with a popula-
tion risk of approximately 5% (Figure 1).5 In contrast,
a variant in TCF7L2, which has the strongest known asso-
ciation with type 2 diabetes risk, increases the relative
odds of developing diabetes by roughly 50%6 but increases
the absolute risk by only a few percent. This distinction
must be communicated clearly tohealth-care professionals,
consumers, and payers. It is also important to realize that
risk results, especially for common diseases, are often based
on association studies that have not been consistently
replicated.7 Furthermore, these results can vary signifi-
cantly among populations.8 In fact, the great majority of
genome-wide association studies have been carried out on
populations of European ancestry, and their results cannot
necessarily be extrapolated to other populations.9
Another important issue is the sensitivity and specificity
of genetic tests. For common diseases in which most of the
genetic causation is presently unknown,10 the sensitivity
of a genetic test is necessarily low. In many cases, the asso-
ciated variants are also common in the general population,
and thus the specificity is not very high either (Figure 1).
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Figure 1. Risk of Developing Colon Cancer or Type 2 Diabetes
for Individuals Who Carry a Disease-Causing Variant in APC or
TCF7L2, Respectively
Risk (%) for variant carriers is compared with risk in the general
population.be aware of the limitations, as well as potential benefits, of
genetic testing.
It is interesting that new technology, such as genetic
testing, is often overrated,whereas accepted science is often
underrated and under-recognized. The latter is certainly
true of the science of evolution. A well-known survey, con-
ducted in 34 different countries, reported the proportion of
the public who accept the science of evolution.11 Although
acceptance is quite high in many European countries, it
remains low in the United States. Another recent survey
showed that 58% percent of Americans believe that evolu-
tion and creationism should be taught together in our
public schools.12 And 38% think that creationism should
be taught instead of evolution in our public schools.
These rather alarming statistics can be attributed, at least
in part, to several common myths about the science of
evolution. I’d like to examine and deconstruct each of
these myths.
One is that evolution is not testable or falsifiable. This
myth itself can be falsified by considering the age of the
Earth. If our planet were only six thousand years old (or
only ten million years old), there wouldn’t have been
enough time for evolution to do its work, and the theory
would be falsified. Charles Darwin was well aware of this.
In his characteristically careful prose, he stated, ‘‘I am
greatly troubled at the short duration of the world accord-
ing to Sir W. Thompson [Lord Kelvin], for I require for my
theoretical views a very long period before the Cambrian
formation’’ (Charles Darwin, in a letter to James Croll,
31 January, 1869). We now have abundant evidence, of
course, that the Earth is old enough to accommodate the
evolution of life in its many forms. Many other such exam-
ples can be cited. Evolutionary theory has been tested
rigorously, over and over again, using the fossil record
and genetic evidence. The evidence has consistently and
overwhelmingly supported the theory of evolution.
We can also test a competing theory, the theory of ‘‘intel-
ligent design’’ (formerly known as creation science). Intel-
ligent design hypotheses are readily falsified by many
features of the human body itself.13 Our lower backs, for
example, are notoriously prone to pain and failure. This388 The American Journal of Human Genetics 90, 387–389, March 9is inconsistent with intelligent design but easily explained
as a consequence of evolution for bipedal locomotion. The
circuitous path of the mammalian vas deferens, ascending
from the testes and looping around the ureters before
descending back to the penis, is a vivid and rather comical
example of unintelligent design. But it can be explained
by evolutionary opportunism as it became necessary for
the testes to migrate outside the body to maintain a cool
temperature in warm-blooded mammals. Nature abounds
with similar examples in which we observe not the
purposeful signature of an intelligent designer, but instead
the opportunistic, and sometimes even whimsical, process
of evolutionary tinkering.14,15
Another commonmyth is that we humans have stopped
evolving. In fact, genetic studiesprovide abundant evidence
of ongoing human evolution: rapid evolution of malarial
resistance, convergentevolutionofhereditary lactasepersis-
tence in African and European herding populations, evolu-
tion of genes that affect skin pigmentation, and the evolu-
tion of genes that affect adaptation to high altitude.16 As
our ability to scanwhole human genomes for adaptive vari-
ation increases, we will doubtless discover many additional
examples of the continuing evolution of our own species.
A thirdmyth is that the theoryof evolution iscontroversial
among scientists. In a 2006 opinion poll, 28% of Americans
responded that scientists disagree seriously about evolution;
10% were ‘‘not sure.’’12 A former US president stated just
several years ago, ‘‘Well, the jury is still out on evolution.’’
This myth is especially concerning because of its obvious
corollary that we should be ‘‘teaching the controversy’’ in
our schools. So what do scientists (the jury) actually think
about evolution? A 2009 AAAS survey of more than 2,500
scientists showed that 97% agree that ‘‘humans and other
living things have evolved over time.’’ This level of agree-
ment in the scientific community is unusual, to say the least.
The jury, in fact, is ‘‘in,’’ and the verdict is unanimous.
A final myth is that the study of evolution has no prac-
tical value. In fact, evolutionary principles have a wide
variety of practical applications. We use them in the
management of wildlife populations; they are used in the
forensic genetic analysis of thousands of criminal cases
each year. Evolutionary principles are also critical in the
analysis of genomic data. They figured prominently in
the designs of the 1000 Genomes Project,17 the Interna-
tional HapMap Project,18 and in countless genome-wide
association studies. Evolutionary principles such as cross-
species conservation (to identify functional variants in
sequence data) and linkage disequilibrium (to design asso-
ciation studies) are applied routinely. And evolution is used
directly in designing vaccines and drugs. For example,
aptamers are created by mutating sequences and then
subjecting them to rounds of in vitro selection (SELEX;
systematic evolution of ligands by exponential enrich-
ment). By mimicking the process of natural selection,
this process has led to a number of drugs that are in phase
II and phase III trials, as well as at least one FDA-approved
drug for the treatment of eye disease.19, 2012
All segments of society can benefit from education about
these and many other aspects of human genetics. Many or
most ASHG members have participated in these educa-
tional endeavors, and I will conclude with a brief descrip-
tion of an area in which I and many ASHG colleagues have
devoted some effort: the education of our judiciary. Much
of this work has been done through a non-profit organiza-
tion, ASTAR (Advanced Science and Technology Adjudi-
cation Resource Center). In two- to three-day training
sessions, judges learn about a variety of genetic topics rele-
vant to their profession:DNA and forensics, genetic testing,
genetically modified foods, gene patenting, evolution and
creationism, stem cells and cloning, and behavior genetics.
This last topic has generated substantial interest among
judges, in part because of recent studies that appear to
show, at least under some circumstances, an association
between antisocial behavior and variation in genes that
encode monoamine oxidase A (MAOA) and the serotonin
transporter.20,21 Genetic test results for these loci have
been introduced as evidence of diminished capacity in
more than a dozen murder cases in the United States.22,23
In a high-profile case in Italy, an appeals court reduced the
sentence of a convicted murderer in part because of his
MAOA and serotonin transporter genotypes.24 These devel-
opments present significant concerns to judges, who are
required increasingly to act as the gatekeepers of courtroom
evidence. They need to understand at least the basic princi-
ples that underlie the genetic evidence presented to them.
Although our efforts in judicial education are necessarily
brief and incomplete, they do help to demystify our science
and to make it more accessible.
Explaining our science clearly to lay audiences is a chal-
lenge, but it presents an opportunity to educate, to
enlighten, and sometimes even to inspire. In doing so, we
will help to close the gaps in human genetics education.
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